These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 348536)

  • 1. Treatment of nausea and vomiting related to anti-cancerous multiple combination chemotherapy: results of two controlled studies.
    Israel L; Rodary C
    J Int Med Res; 1978; 6(3):235-40. PubMed ID: 348536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled studies of metopimazine for the treatment of nausea and vomiting.
    Moertel CG; Reitemeier RJ
    J Clin Pharmacol; 1973 Jul; 13(7):283-7. PubMed ID: 4576417
    [No Abstract]   [Full Text] [Related]  

  • 3. [Double blind randomized trial of metopimazine: for postoperative nausea and vomiting after cholecystectomy].
    Rodary C; Elman A; Durand M; Cohen-Solal J; Maillard JN
    Ann Anesthesiol Fr; 1979; 20(2):118-20. PubMed ID: 38705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer.
    Herrstedt J; Sigsgaard T; Handberg J; Schousboe BM; Hansen M; Dombernowsky P
    J Clin Oncol; 1997 Apr; 15(4):1690-6. PubMed ID: 9193370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis.
    Khamales S; Bethune-Volters A; Chidiac J; Bensaoula O; Delgado A; Di Palma M
    Anticancer Drugs; 2006 Feb; 17(2):217-24. PubMed ID: 16428941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy.
    Sigsgaard T; Herrstedt J; Handberg J; Kjaer M; Dombernowsky P
    J Clin Oncol; 2001 Apr; 19(7):2091-7. PubMed ID: 11283143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A double-blind study of alizapride in nausea and emesis induced by cancer chemotherapeutic agents (author's transl)].
    Viala JJ; Girard D; Cordier JF
    Sem Hop; 1982 Feb; 58(6):371-4. PubMed ID: 6280306
    [No Abstract]   [Full Text] [Related]  

  • 8. Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy.
    Sigsgaard T; Herrstedt J; Andersen LJ; Havsteen H; Langer SW; Kjaerbøl AG; Lund H; Kjaer M; Dombernowsky P
    Br J Cancer; 1999 May; 80(3-4):412-8. PubMed ID: 10408847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy.
    Bloch J; Rixe O; Meric JB; Delgado A; Khayat D
    Curr Med Res Opin; 2005 Nov; 21(11):1763-71. PubMed ID: 16307696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy.
    Herrstedt J; Sigsgaard T; Boesgaard M; Jensen TP; Dombernowsky P
    N Engl J Med; 1993 Apr; 328(15):1076-80. PubMed ID: 8455664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-induced nausea and vomiting with special emphasis on metopimazine.
    Herrstedt J
    Dan Med Bull; 1998 Sep; 45(4):412-22. PubMed ID: 9777292
    [No Abstract]   [Full Text] [Related]  

  • 14. Lorazepam: a randomized, double-blind, crossover study of a new antiemetic in patients receiving cytotoxic chemotherapy and prochlorperazine.
    Bishop JF; Olver IN; Wolf MM; Matthews JP; Long M; Bingham J; Hillcoat BL; Cooper IA
    J Clin Oncol; 1984 Jun; 2(6):691-5. PubMed ID: 6374058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ondansetron in the treatment of nausea and vomiting. Introduction.
    Marschner N
    Anticancer Drugs; 1993 Dec; 4 Suppl 2():3-7. PubMed ID: 8136513
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial.
    Kang HJ; Loftus S; Taylor A; DiCristina C; Green S; Zwaan CM
    Lancet Oncol; 2015 Apr; 16(4):385-94. PubMed ID: 25770814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trimethobenzamide HCl in the treatment of nausea and vomiting associated with antineoplastic chemotherapy.
    Hurley JD; Eshelman FN
    J Clin Pharmacol; 1980; 20(5-6 Pt 1):352-6. PubMed ID: 7400373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study.
    Mizukami N; Yamauchi M; Koike K; Watanabe A; Ichihara K; Masumori N; Yamakage M
    J Pain Symptom Manage; 2014 Mar; 47(3):542-50. PubMed ID: 23856100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.